AstraZeneca's COVID-19 Vaccine Boosts Immune Response in Older, Younger Adults

Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.